CUAMC
APLS

China Universal Asset Management Company’s Apellis Pharmaceuticals APLS Stock Holding History

China Universal Asset Management Company’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-22,684
Closed -$913K – 517
2026
Q1 		$913K Buy
22,684
+2,067
+10% +$44.5K 0.07% 202
2025
Q4 		$518K Sell
20,617
-1,520
-7% -$35.7K 0.04% 257
2025
Q3 		$501K Sell
22,137
-3,106
-12% -$72.4K 0.04% 249
2025
Q2 		$437K Buy
25,243
+67
+0.3% +$1.24K 0.04% 250
2025
Q1 		$551K Sell
25,176
-1,200
-5% -$33.1K 0.05% 241
2024
Q4 		$842K Buy
26,376
+2,956
+13% +$88.9K 0.08% 184
2024
Q3 		$675K Buy
23,420
+9,160
+64% +$339K 0.07% 184
2024
Q2 		$547K Sell
14,260
-8,922
-38% -$404K 0.08% 138
2024
Q1 		$1.36M Buy
23,182
+9,472
+69% +$604K 0.17% 106
2023
Q4 		$821K Buy
13,710
+10,682
+353% +$542K 0.16% 122
2023
Q3 		$115K Buy
3,028
+687
+29% +$30.2K 0.03% 190
2023
Q2 		$213K Sell
2,341
-25
-1% -$2.16K 0.07% 128
2023
Q1 		$156K Buy
2,366
+1,243
+111% +$71.7K 0.05% 121
2022
Q4 		$58.1K Buy
1,123
+94
+9% +$4.99K 0.02% 134
2022
Q3 		$70K Buy
+1,029
New +$60.9K 0.03% 118

Other funds holding APLS

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

China Universal Asset Management Company's APLS Position: Q2 2026 in Review

China Universal Asset Management Company sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 22,684 shares — an estimated $913K sold.

China Universal Asset Management Company first reported a position in APLS in Q3 2022 and held it in 15 quarters. The position peaked at $1.36M in Q1 2024. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

  • China Universal Asset Management Company reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • China Universal Asset Management Company sold 22,684 Apellis Pharmaceuticals shares in Q2 2026, an estimated $913K.
  • China Universal Asset Management Company first reported a position in Apellis Pharmaceuticals in Q3 2022 and held it in 15 quarters.
  • China Universal Asset Management Company's Apellis Pharmaceuticals position peaked at $1.36M in Q1 2024.
  • 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on China Universal Asset Management Company's 13F filing for Q2 2026, filed 24 Jul 2026.